Open AccessPharmacokinetics of Nevirapine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their Neonates
Author(s) -
Mark Mirochnick,
Terry Fenton,
Paul Gagnier,
Joseph Pav,
Margaret Gwynne,
Suzanne Siminski,
R S Sperling,
Karen Beckerman,
Esther Jiménez,
Ram Yogev,
Stephen A. Spector,
J L Sullivan
Publication year - 1998
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/515641
Subject(s) - nevirapine , pharmacokinetics , dosing , medicine , adverse effect , physiology , pregnancy , obstetrics , pharmacology , human immunodeficiency virus (hiv) , virology , biology , viral load , antiretroviral therapy , genetics
The safety, toxicity, and pharmacokinetics of intrapartum and early newborn nevirapine were evaluated in 17 human immunodeficiency virus type 1-infected women in labor and their newborns. No adverse effects of nevirapine were noted in any study mothers or infants. Following maternal dosing with 200 mg during labor, concentrations exceeding 100 ng/mL (10 times the in vitro IC50) were achieved in the newborns. Nevirapine elimination was prolonged in both mothers and infants, with median half-lives ranging from 36.8 to 65.7 h. Administration of 200 mg orally to the mothers in labor and of a single 2-mg/kg oral dose to the infants at 48-72 h after birth maintained serum concentrations in the infants > 100 ng/mL through 7 days of life.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom